Ivermectin 200 mcg/kg once orally on empty stomach plus Nitazoxanide 500 mg twice daily orally with meal for 6 days

COVID-19

Ivermectin plus Nitazoxanide

Standard Care

Ivermectin and Nitazoxanide Combination Therapy for COVID-19

Clinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope

improved breaths per minute for the patients

Serum iron in microgram/dL of the patients

Serum ferritinin microgram/L of the patients

International normalized ratio "INR" for prothrombin time of 2

CBC for lymphocyte count in cells/microliter

Mortality rate [number of dead patients/total number of treated patients]

Prof. Dr. Kamal Mohammed Okasha

Vice-President of Postgraduate Studies and Research Affairs

Tanta University

This study will be a double blind randomized controlled parallel study

Emtricitabine 200mg/tenofovir alafenamide 25mg (FTC/TAF) tablet to be given orally once daily to be added to a failing regimen for 10 days. If HIV RNA decline by >= 0.5 log copies/mL, patient will continue on FTC/TAF with a new antiretroviral regimen for 48 weeks. If < 0.5 log copies/mL decline, patient will be taken off FTC/TAF.

Each subject receives tenofovir alafenamide (TAF) with emtricitabine to be added to a failing antiretroviral regimen for 10 days, if there is a HIV RNA response of >= 0.5 log decline, subjects will continue of TAF with emtricitabine with a new optimized background regimen. If <0.5 log decline, TAF with emtricitabine will be discontinued and study enrollment for the subject will be terminated.

TAF Treatment

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

An HIV RNA decline of >=0.5 log by day 10 will be considered to be an adequate virologic response, to proceed to the second phase of the study.

HIV RNA Change From Baseline to Day 10

Overall Study

Alice Pau, Pharm.D., Staff Scientist (Clinical)

Tenofovir alafenamide (TAF) is an investigational oral prodrug of tenofovir. This trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part of a salvage antiretroviral regimen for HIV-1-infected adults and adolescents (greater than or equal to 14 years) who experienced virologic failure.

FTC/TAF

National Institutes of Health Clinical Center, 9000 Rockville Pike

Emtricitabine/Tenofovir Alafenamide as Salvage ART

Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide as Part of Salvage Antiretroviral Regimens in Patients With Uncontrolled Viremia and Drug-Resistant HIV Infection

National Institute of Allergy and Infectious Diseases (NIAID)

Anal Cancer

Tempol gel will be applied to the bilateral groins and the gluteal cleft, avoiding a 3 cm radius from the anal verge, immediately prior to each fraction of RT.

Tempol

5-FU will be delivered as 1000mg/m2/day as 96 hour continuous infusion beginning on day 1 and 29.

5-Fluorouracil

MMC will be delivered at a dose of 10mg/m2 on days 1 and 29

Mitomycin-C

RT will be delivered to a total dose of 50-54 Gy based on tumor characteristics.

Radiation Therapy

Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

A Pilot Trial Assessing the Feasibility of Delivering Topical MTS-01 to Reduce Dermatitis in Patients Receiving Intensity Modulated Radiation With Concurrent 5-Fluorouracil and Mitomycin-C for Stage I-III Carcinoma of the Anal Canal

viremia/diarrhea

Ivermectin and Nitazoxanide Combination Therapy for COVID-19

Emtricitabine/Tenofovir Alafenamide as Salvage ART

Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

科学支持的最完整的草药数据库